250 related articles for article (PubMed ID: 17188020)
1. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.
Lewis EF; Lamas GA; O'Meara E; Granger CB; Dunlap ME; McKelvie RS; Probstfield JL; Young JB; Michelson EL; Halling K; Carlsson J; Olofsson B; McMurray JJ; Yusuf S; Swedberg K; Pfeffer MA;
Eur J Heart Fail; 2007 Jan; 9(1):83-91. PubMed ID: 17188020
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).
Wong CM; Hawkins NM; Jhund PS; MacDonald MR; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Petrie MC; McMurray JJ
J Am Coll Cardiol; 2013 Nov; 62(20):1845-54. PubMed ID: 23850914
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.
Hawkins NM; Wang D; McMurray JJ; Pfeffer MA; Swedberg K; Granger CB; Yusuf S; Pocock SJ; Ostergren J; Michelson EL; Dunn FG;
Eur J Heart Fail; 2007 May; 9(5):510-7. PubMed ID: 17317308
[TBL] [Abstract][Full Text] [Related]
4. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
Ostergren JB
J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
[TBL] [Abstract][Full Text] [Related]
6. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
Cohen-Solal A; McMurray JJ; Swedberg K; Pfeffer MA; Puu M; Solomon SD; Michelson EL; Yusuf S; Granger CB;
Eur Heart J; 2008 Dec; 29(24):3022-8. PubMed ID: 18987098
[TBL] [Abstract][Full Text] [Related]
7. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
MacDonald MR; Petrie MC; Varyani F; Ostergren J; Michelson EL; Young JB; Solomon SD; Granger CB; Swedberg K; Yusuf S; Pfeffer MA; McMurray JJ;
Eur Heart J; 2008 Jun; 29(11):1377-85. PubMed ID: 18413309
[TBL] [Abstract][Full Text] [Related]
8. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
Wolsk E; Claggett B; Køber L; Pocock S; Yusuf S; Swedberg K; McMurray JJV; Granger CB; Pfeffer MA; Solomon SD
Eur J Heart Fail; 2018 Mar; 20(3):504-510. PubMed ID: 29193462
[TBL] [Abstract][Full Text] [Related]
9. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.
Castagno D; Skali H; Takeuchi M; Swedberg K; Yusuf S; Granger CB; Michelson EL; Pfeffer MA; McMurray JJ; Solomon SD;
J Am Coll Cardiol; 2012 May; 59(20):1785-95. PubMed ID: 22575317
[TBL] [Abstract][Full Text] [Related]
10. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
McMurray JJ; Andersson FL; Stewart S; Svensson K; Solal AC; Dietz R; Vanhaecke J; van Veldhuisen DJ; Ostergren J; Granger CB; Yusuf S; Pfeffer MA; Swedberg K
Eur Heart J; 2006 Jun; 27(12):1447-58. PubMed ID: 16754631
[TBL] [Abstract][Full Text] [Related]
11. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Chandra A; Vaduganathan M; Lewis EF; Claggett BL; Rizkala AR; Wang W; Lefkowitz MP; Shi VC; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV; Solomon SD;
JACC Heart Fail; 2019 Oct; 7(10):862-874. PubMed ID: 31302043
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin inhibition in heart failure.
McMurray JJ
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S17-22. PubMed ID: 15526237
[TBL] [Abstract][Full Text] [Related]
13. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
Kristensen SL; Køber L; Jhund PS; Solomon SD; Kjekshus J; McKelvie RS; Zile MR; Granger CB; Wikstrand J; Komajda M; Carson PE; Pfeffer MA; Swedberg K; Wedel H; Yusuf S; McMurray JJ
Circulation; 2015 Jan; 131(1):43-53. PubMed ID: 25406306
[TBL] [Abstract][Full Text] [Related]
14. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M;
Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720
[TBL] [Abstract][Full Text] [Related]
15. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
Ducharme A; Swedberg K; Pfeffer MA; Cohen-Solal A; Granger CB; Maggioni AP; Michelson EL; McMurray JJ; Olsson L; Rouleau JL; Young JB; Yusuf S
Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644318
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme.
Chang SM; Granger CB; Johansson PA; Kosolcharoen P; McMurray JJ; Michelson EL; Murray DR; Olofsson B; Pfeffer MA; Solomon SD; Swedberg K; Yusuf S; Dunlap ME;
Eur J Heart Fail; 2010 Jul; 12(7):738-45. PubMed ID: 20418272
[TBL] [Abstract][Full Text] [Related]
17. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients.
Solomon SD; Anavekar N; Skali H; McMurray JJ; Swedberg K; Yusuf S; Granger CB; Michelson EL; Wang D; Pocock S; Pfeffer MA;
Circulation; 2005 Dec; 112(24):3738-44. PubMed ID: 16330684
[TBL] [Abstract][Full Text] [Related]
18. Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
O'Meara E; Lewis E; Granger C; Dunlap ME; McKelvie RS; Probstfield JL; Young JB; Michelson EL; Ostergren J; Carlsson J; Olofsson B; McMurray J; Yusuf S; Swedberg K; Pfeffer MA
Eur J Heart Fail; 2005 Jun; 7(4):650-6. PubMed ID: 15921807
[TBL] [Abstract][Full Text] [Related]
19. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
Yusuf S; Pfeffer MA; Swedberg K; Granger CB; Held P; McMurray JJ; Michelson EL; Olofsson B; Ostergren J;
Lancet; 2003 Sep; 362(9386):777-81. PubMed ID: 13678871
[TBL] [Abstract][Full Text] [Related]
20. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
Pocock S; Wang D; Wilhelmsen L; Hennekens CH
Am Heart J; 2005 May; 149(5):939-43. PubMed ID: 15894981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
